Interview with Sarina Shabso, 2024 Daniel Alagille Awardee
The recipient of the 2024 Daniel Alagille Award, Sarina Shabso, discusses her inspiring journey into the field of hepatology. Shabso's path, from her early focus on skin regeneration to her groundbreaking research…
Interview with Scott Waddell, 2023 Daniel Alagille Awardee
In an insightful conversation with EASL, Scott Waddell, the recipient of the 2023 Daniel Alagille Award, shares his journey into the field of hepatology. From his initial focus on cholangiocarcinoma to his…
Join the EASL Educational Committee!
The EASL Educational Committee provides scientific expertise and support to the EASL Governing Board and EASL office, in the development and monitoring of a high-quality portfolio of educational offerings in support of…
European Medicines Association (EMA) statement on Obeticholic acid for the treatment of primary biliary cholangitis (PBC) European Association for the Study of the Liver (EASL) perspective
The EMA human medicines committee (CHMP) has recently issued a statement on Obeticholic acid for the treatment of Primary Biliary Cholangitis (PBC). The CHMP recommended to the European Commission that the market…
First Patient Enrolled in Phase II Clinical Trial of DECISION’s COMBAT Trial
• First patient enrolled at Hôpital Beaujon, Clichy, France • The COMBAT Trial is a multicenter, randomized, open-label, Phase II clinical trial in patients with decompensated cirrhosis Barcelona, Spain, 9th July 2024…
EASL announces JHEP Reports’ Impact Factor of 9.5 for 2023
The European Association for the Study of the Liver (EASL)is delighted to announce that JHEP Reports, its Open Access publication, achieved an impressive impact factor of 9.5 in the 2024 release of…
EASL announces Journal of Hepatology’s exceptional Impact Factor of 26.8 for 2023
The European Association for the Study of the Liver (EASL) is proud to announce that the Journal of Hepatology, its flagship publication, achieved an impact factor of 26.8 in the 2024 release…